 |
 |
"Biovail, Valeant to Merge, Creating Specialty Pharma Powerhouse Biovail, one of Canada’s largest drugmakers, and Valeant Pharmaceuticals will merge in a deal that will create one of the largest specialty pharma companies. The combined company will focus on four core growth areas: specialty central nervous system, dermatology, Canada and emerging markets/branded generics. As a result of the merger, between 15 percent to 20 percent of the companies’ employees will be laid off, Biovail and Valeant executives said Monday. The new company will take the Valeant name and its CEO, J. Michael Pearson, will keep that role in the combined company, which will be based in Ontario. " From Drug Industry Daily Biovail is one of the companies developing a new delivery method for GDNF -- together with MedGenesis. After 6 years since the last study was terminated they received the license from amgen to restart the work on GDNF They also justt received a grant from the Fox Foundation. see: http://michaeljfox.org/newsEvents_mjffInTheNews_events_article.cfm?ID=423 Keep your eyes on this one! www.pdpipeline.org ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn